NCT07792980Recruiting
AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients
AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients: A 13-Week, Randomized, Double-Blind, Placebo-Controlled Trial (AI-MPRO3 Study)
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the effects of MPRO3(probiotics mixture) supplementation on surgical outcomes and gut health in patients undergoing surgery for colon cancer.The main question is whether MPRO3 supplementation before and after surgery can reduce postoperative infectious complications compared with placebo.Participants will take either MPRO3 or a placebo once daily for 13 weeks, from 1 week before surgery to 12 weeks after surgery. Researchers will compare the two groups to assess postoperative infectious complications, other clinical outcomes, and changes in the gut microbiome.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 19 Aug 2026
- Start date
- Aug 2026
- Primary completion date
- Apr 2028
- Lead sponsor
- hy Co., LTD.
- Diseases
- Colorectal cancer
- NCT number
- NCT07792980
What you commit to
- Study type: Interventional
- Planned participants: 100
- From Aug 2026 to the primary completion date, Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A person who has received chemotherapy or radiotherapy for colon cancer before surgery
- A person who is currently diagnosed with or receiving treatment for another type of cancer
- A person who has continuously used probiotics within the previous week
- A person who has hypersensitivity to the investigational product or any of its ingredients, or an allergy to a specific ingredient
- A person who has participated in another human study or drug clinical trial within one month before the start of this study, except for a study involving only non-invasive surveys
Other illness
- A person who has been diagnosed with an acute or serious disease, such as liver, kidney, heart, or thyroid disease, or is taking related medication
- A person with alcohol dependence or a history of drug abuse
- A person with immune system disorders, infectious diseases, or gastrointestinal diseases, including inflammatory bowel disease
Lab values
- A person with renal dysfunction, defined as serum creatinine at least 1.5 times the upper limit of normal, or liver dysfunction, defined as AST and/or ALT at least 2.5 times the upper limit of normal
Other
- A person with fecal incontinence
- A person who is pregnant or lactating
- A person who is unable to read letters or whose ability is limited
- A person deemed inappropriate by the investigator to participate in this study for other reasons
Who the study is looking for
- A person who is diagnosed histologically or radiologically with adenocarcinoma of the colon and is scheduled to undergo surgery
Age in the registry: 20 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul St. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.